Mumbai: Pharmaceutical firm GlaxoSmithKline (GSK) Pharma has signed an agreement with Daiichi Sankyo India Pharma Limited (DSIPL) for jointly promoting the anti-hypertensive drug Olmesartan Medoxomil and its combination products.
GSK India has signed a co-promotion agreement with DSIPL, which is a subsidiary of Japan-based pharmaceutical company Daiichi Sanko Company Limited.
“This agreement comes close on the heels of our in-licensing agreement for Micafungin last week. Our strategy as laid out at the beginning of the year of in-licencing products in specific high growth therapeutic areas is being rolled out and is well on track,” GSK India managing director, Hasit Joshipura said.
Olmesartan is a $2 billion worth drug for Daiichii and is available in more than 50 countries worldwide, the company said in a filing to the Bombay Stock Exchange.
With this launch, Daiichi Sankyo India would mark its entry into India and pave the way for many more research products to be introduced in the future, Daiichi Sankyo India president V Vijayendran said.
Shares of GSK India were trading at Rs1,058, up 1.33% on the BSE in morning trade.